| Name | Lanreotide |
|---|---|
| Synonyms |
B-NAPHTHYL-D-ALA-CYS-TYR-D-TRP*LYS-VAL-C YS-THR AMID
Lanreotide Acetate(net) (4R,7S,10S,13R,16S,19R)-13-((1H-Indol-3-yl)methyl)-19-((R)-2-amino-3-(naphthalen-2-yl)propanamido)-N-((2S,3R)-1-amino-3-hydroxy-1-oxobutan-2-yl)-10-(4-aminobutyl)-16-(4-hydroxybenzyl)-7-isopropyl-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentaazacycloicosane-4-cboxamide L-Threoninamide, 3-(2-naphthalenyl)-D-alanyl-L-cysteinyl-L-Tyrosyl-D-tryptophyl-L-lysyl-L-valyl-L-cysteinyl-, cyclic disulfide, TFA salt 10-(4-Aminobutyl)-N-(1-amino-3-hydroxy-1-oxo-2-butanyl)-16-(4-hydroxybenzyl)-13-(1H-indol-3-ylmethyl)-7-isopropyl-19-{[3-(2-naphthyl)alanyl]amino}-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentaazacycloicosane-4-carboxamide BETA-(2-NAPHTHYL)-D-ALA-CYS-TYR-D-TRP-LYS-VAL-CYS-THR AMIDE T4 40mcg, 100 tablets Lanreotide //BP 3-(2-Naphtyl)-D-Ala-L-Cys-L-Tyr-D-Trp-L-Lys-L-Val-L-Cys-L-Thr-NH2 *Tributyl Acetylcitrate Impurity 7 β-(2-naphthyl)-d-ala-cys-tyr-d-trp-lys-val-cys-thr amide [disulfide bridge: ] (D-2-NAL5,CYS6,11,TYR7,D-TRP8,VAL10)-SOMATOSTATIN AMIDE DC-13-116, Angioptin, (D-2-Nal5,Cys6'11,Tyr7,D-Trp8,Val10)-SoMatostatin aMide, BIM-23014, (D-2-Nal5,Cys6·11,Tyr7,D-Trp8,Val10)-SoMatostatin aMide AUTOGEL ANGIOPEPTIN LANREOTIDE Lanreotide, Somatostatin rector analog B-naphthyl-D-ala-cys-tyr-D-trp*lys-val-cys-thr am TIANFUCHEM--108-2--Lanreotide bim-23014c Somatuline LanreotideAcetate impurity DC-13-116 Lanreotide, Angioptin 10-(4-Aminobutyl)-N-(1-amino-3-hydroxy-1-oxobutan-2-yl)-16-(4-hydroxybenzyl)-13-(1H-indol-3-ylmethyl)-7-isopropyl-19-{[3-(2-naphthyl)alanyl]amino}-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentaazacycloicosane-4-carboxamide ANGIOPTIN H-D-2-NAL-CYS-TYR-D-TRP-LYS-VAL-CYS-THR-NH2 H-D-2-NAL-CYS-TYR-D-TRP-LYS-VAL-CYS-THR-NH2, (DISULFIDE BOND) LoMustine L-Threoninamide,3-(2-naphthalenyl)-D-alanyl-L-cysteinyl-L-tyrosyl-D-tryptophyl-L-lysyl-L-valyl-L-cysteinyl-,cyclic (2® 3-(2-Naphthalenyl)-D-alanyl-L-cysteinyl-L-tyrosyl-D-tryptophyl-L-lysyl-L-valyl-L-cysteinyl-L-threoninamide cyclic -disulfide BIM-23014 Lanreotide D8Q: What is Lanreotide D8 Q: What is the CAS Number of Lanreotide D8 Q: What is the storage condition of Lanreotide D8 Q: What e the applications of Lanreotide D8 Lanreotide Ditrifluoroacetate (4R,7S,10S,13R,16S,19R)-10-(4-aminobutyl)-N-[(2S,3R)-1-amino-3-hydroxy-1-oxobutan-2-yl]-19-[[(2R)-2-amino-3-naphthalen-2-ylpropanoyl]amino]-16-[(4-hydroxyphenyl)methyl]-13-(1H-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-7-propan-2-yl-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-cboxamide IPSTYL D-βNal-L-Cys(1)-L-Tyr-D-Trp-L-Lys-L-Val-L-Cys-L-Thr-NH2 Lanreotide Angioptin acetate D8-Lanreotide |
| Description | Lanreotide (BIM 23014) is a somatostatin analogue with antineoplastic activity. Lanreotide can be used for the research of carcinoid syndrome[1][2]. |
|---|---|
| Related Catalog | |
| In Vitro | Lanreotide (BIM 23014) (100 nM; 24-48 h) combines with radiation increasing in apoptotic sub-G1 proportion[1]. Lanreotide results in a dose-dependent decrease in GH3 cell colony forming units. Lanreotide at concentrations of 1, 10, 100, and 1000 nM results in cell survival rates of 75, 56, 39 and 27% respectively. The IC50 is 57 nM[1]. Lanreotide inhibits GH-secreting pituitary adenoma cell proliferation and hormone release in vitro[2]. |
| In Vivo | Lanreotide (2.5-10mg/kg; s.c.; daily for 5 days) results in tumor growth inhibition[1]. Animal Model: Male nude mice, 8 weeks old and 20–25 g in body weight (GH3 tumor-bearing nude mice)[1] Dosage: 2.5, 5, 10 mg/kg Administration: Subcutaneous; daily for 5 days Result: Produced tumor growth inhibition. |
| References |
| Density | 1.4±0.1 g/cm3 |
|---|---|
| Boiling Point | 1508.2±65.0 °C at 760 mmHg |
| Molecular Formula | C54H69N11O10S2 |
| Molecular Weight | 1096.323 |
| Flash Point | 865.9±34.3 °C |
| Exact Mass | 1095.467041 |
| PSA | 405.68000 |
| LogP | 2.89 |
| Vapour Pressure | 0.0±0.3 mmHg at 25°C |
| Index of Refraction | 1.689 |